Novo Nordisk (NVO) is up 6.4% today. Here is some analysis on what might have caused this price movement.
Analysis: The move appears tied to renewed optimism around Novo Nordisk’s obesity franchise after a string of favorable updates this month. Investors likely focused on strong early demand for the Wegovy pill, a new UK approval for the product, and encouraging late-stage CagriSema data, while management’s comments about a possible China filing may have added to the bullish tone.
Details:
Novo Nordisk said on June 7 that Wegovy pill had surpassed 3 million prescriptions in the U.S. in a little over five months, with most new starts coming from people new to GLP-1 treatment.On June 11, the company announced that the UK approved Wegovy pill, giving patients a daily oral option and marking the first approval of the product in Europe.Novo Nordisk also presented phase 3 REIMAGINE data showing CagriSema delivered significant reductions in both blood sugar and body weight across multiple studies in adults with type 2 diabetes.Management recently indicated that a China submission for oral Wegovy could come within months, which may have supported expectations for another large-market expansion opportunity.Sources:
Novo Nordisk, AP News, Cinco Días
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
Quiver Alerts
Receive NVO Data Alerts
Get market-moving data, filings, and signals for NVO in real time.
Sign Up
$NVO Hedge Fund Activity
We have seen 570 institutional investors add shares of $NVO stock to their portfolio, and 902 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DODGE & COX added 19,333,750 shares (+inf%) to their portfolio in Q1 2026, for an estimated $693,211,606
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 9,884,077 shares (+808.8%) to their portfolio in Q1 2026, for an estimated $354,393,580
- FMR LLC removed 8,664,705 shares (-86.5%) from their portfolio in Q1 2026, for an estimated $310,672,997
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 7,827,491 shares (+inf%) to their portfolio in Q1 2026, for an estimated $280,654,689
- TWO SIGMA INVESTMENTS, LP added 5,943,310 shares (+1731.8%) to their portfolio in Q1 2026, for an estimated $213,097,380
- GOLDMAN SACHS GROUP INC removed 5,865,741 shares (-53.4%) from their portfolio in Q1 2026, for an estimated $210,316,143
- BOSTON PARTNERS removed 5,231,804 shares (-97.3%) from their portfolio in Q1 2026, for an estimated $187,586,332
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$NVO Price Targets
Multiple analysts have issued price targets for $NVO recently. We have seen 2 analysts offer price targets for $NVO in the last 6 months, with a median target of $57.25.
Here are some recent targets:
- James Quigley from Goldman Sachs set a target price of $41.0 on 03/02/2026
- An analyst from CICC set a target price of $73.5 on 01/09/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Read full article here »
View the Zacks #1 Rank List
Novo Nordisk Jumps as Investors Cheer Wegovy Pill Momentum and Pipeline Updates
Novo Nordisk (NVO) is up 6.4% today. Here is some analysis on what might have caused this price movement.
Analysis: The move appears tied to renewed optimism around Novo Nordisk’s obesity franchise after a string of favorable updates this month. Investors likely focused on strong early demand for the Wegovy pill, a new UK approval for the product, and encouraging late-stage CagriSema data, while management’s comments about a possible China filing may have added to the bullish tone.
Details:
Sources:
Novo Nordisk, AP News, Cinco Días
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$NVO Hedge Fund Activity
We have seen 570 institutional investors add shares of $NVO stock to their portfolio, and 902 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$NVO Price Targets
Multiple analysts have issued price targets for $NVO recently. We have seen 2 analysts offer price targets for $NVO in the last 6 months, with a median target of $57.25.
Here are some recent targets:
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Read full article here »